Magnetic resonance

The world’s oldest conjoined twins have died – what we know about this rare condition

Retrieved on: 
Friday, April 19, 2024

The world’s oldest conjoined twins, Lori and George Schappell, recently died, aged 62.

Key Points: 
  • The world’s oldest conjoined twins, Lori and George Schappell, recently died, aged 62.
  • Conjoined twins are incredibly rare, accounting for about one or two in every 100,000 births.
  • Because conjoined twins are so rare, it is difficult to know exactly how they come about.

Types of conjoined twins

  • There are 15 recognised types of conjoined twins, based on the various places their bodies fuse.
  • Conjoined twins are usually picked up on routine ultrasound scans performed during pregnancy.
  • Conjoined twins who are diagnosed by imaging are typically delivered by caesarean section.

Separating twins

  • One of the longest operations to separate conjoined twins, who were fused at the cranium, took more than 100 hours.
  • The earliest recorded attempt at surgical separation of conjoined twins dates back to AD945 in Armenia where conjoined brothers lived until middle age before one of them died.
  • Separating conjoined twins requires a significant amount of planning before surgery can begin, including, of course, lots of imaging such as ultrasound, CT and MRI.
  • Twins who share vital organs – or whose organs are fused – have a lower chance of a successful separation.


Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Retrieved on: 
Wednesday, April 3, 2024

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that dosing in the Phase 2a HERALD study of ALG-055009 has been initiated in subjects with metabolic dysfunction-associated steatohepatitis (MASH).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that dosing in the Phase 2a HERALD study of ALG-055009 has been initiated in subjects with metabolic dysfunction-associated steatohepatitis (MASH).
  • “Dosing the first subjects in our Phase 2a HERALD study is an important milestone for Aligos,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • “We are pleased by the engagement of the clinicians and subjects, demonstrating the need for additional oral MASH therapies.
  • Topline safety and efficacy data from this study are expected in Q4 2024.

Q Bio Unveils New MRI Technology - Tensor Field Mapping - Advancing Measurement in Medical Imaging

Retrieved on: 
Tuesday, April 9, 2024

Q Bio Inc. , an innovator in medical imaging technology, today announced the launch of Tensor Field Mapping (TFM) , a new technology for Magnetic Resonance Imaging (MRI) that provides detailed insights into the human body that were previously unimaginable.

Key Points: 
  • Q Bio Inc. , an innovator in medical imaging technology, today announced the launch of Tensor Field Mapping (TFM) , a new technology for Magnetic Resonance Imaging (MRI) that provides detailed insights into the human body that were previously unimaginable.
  • "Tensor Field Mapping is more than an innovative technology; it's a vision for the future of medical imaging where frequency, accuracy, and benchmarking with commodity radiomic data is possible," added Clarissa Shen, COO, Q Bio.
  • Q Bio Inc. is committed to advancing medical imaging technology and improving patient outcomes.
  • With the launch of Tensor Field Mapping, the company is at the forefront of a new era in diagnostics and personalized medicine.

TMS Health and Wellness Introduces Cutting-Edge Brain Scanning For Enhanced TMS Therapy Effectiveness

Retrieved on: 
Monday, April 8, 2024

COSTA MESA, Calif., April 8, 2024 /PRNewswire-PRWeb/ -- In a significant advancement for treating anxiety, depression, and other mental health conditions, TMS Health and Wellness proudly announces the integration of comprehensive brain scanning technology into its Transcranial Magnetic Stimulation (TMS) Therapy protocols. This pioneering approach, leveraging Full Brain Scans and Functional MRI (fMRI) is set to revolutionize treatment customization, potentially elevating TMS Therapy's effectiveness to an unprecedented 90%.

Key Points: 
  • This pioneering approach, leveraging Full Brain Scans and Functional MRI (fMRI) is set to revolutionize treatment customization, potentially elevating TMS Therapy's effectiveness to an unprecedented 90%.
  • By utilizing detailed brain imaging to map and understand each patient's unique neural patterns, TMS Health and Wellness can customize the application of TMS Therapy with greater precision than ever before.
  • The clinic's expanded services now include:
    With the introduction of brain scanning technology, TMS Health and Wellness reinforces its dedication to pioneering in the mental health space and its mission of treating the "whole person."
  • TMS Therapy enhanced with Full Brain Scans and Functional MRI is available now.

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Retrieved on: 
Monday, March 18, 2024

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH). Screening of subjects has begun at clinical study sites across the U.S.

Key Points: 
  • The Phase 2a study is being led by Principal Investigator, Dr. Stephen Harrison
    SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH).
  • Screening of subjects has begun at clinical study sites across the U.S.
    “ALG-055009 has enhanced potency, greater beta selectivity, and a favorable PK profile.
  • We believe that these optimized pharmacologic properties may result in improved therapeutic outcomes for patients living with MASH.
  • The initiation of the HERALD study is an important next step in achieving our goal to create a best-in-class thyroid hormone receptor beta agonist,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and CEO of Aligos Therapeutics.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

PolyU research reveals significant effects of instructors onscreen during video classes in aiding student learning

Retrieved on: 
Monday, March 25, 2024

Researchers from The Hong Kong Polytechnic University (PolyU) have conducted a study to analyse whether and how the instructor's presence in online video lectures affected student learning and learning outcomes.

Key Points: 
  • Researchers from The Hong Kong Polytechnic University (PolyU) have conducted a study to analyse whether and how the instructor's presence in online video lectures affected student learning and learning outcomes.
  • The results reveal that students are more motivated to perform socio-emotional and cognitive processing when an instructor, human or animated, is present onscreen, hence facilitating more effective learning.
  • Previous studies have indicated that socio-emotional cues, such as human facial expressions and gestures, help students understand and stay focused on learning content.
  • This contributes to the development of an evidence-based instructional design for multimedia learning, thereby enhancing student's learning experience and outcome."

PolyU research reveals significant effects of instructors onscreen during video classes in aiding student learning

Retrieved on: 
Monday, March 25, 2024

Researchers from The Hong Kong Polytechnic University (PolyU) have conducted a study to analyse whether and how the instructor's presence in online video lectures affected student learning and learning outcomes.

Key Points: 
  • Researchers from The Hong Kong Polytechnic University (PolyU) have conducted a study to analyse whether and how the instructor's presence in online video lectures affected student learning and learning outcomes.
  • The results reveal that students are more motivated to perform socio-emotional and cognitive processing when an instructor, human or animated, is present onscreen, hence facilitating more effective learning.
  • Previous studies have indicated that socio-emotional cues, such as human facial expressions and gestures, help students understand and stay focused on learning content.
  • This contributes to the development of an evidence-based instructional design for multimedia learning, thereby enhancing student's learning experience and outcome."

GrayMatters Health Named as "Most Innovative Company" by Fast Company Magazine for Novel Self-Neuromodulation PTSD Treatment

Retrieved on: 
Tuesday, March 19, 2024

"Introducing a new treatment modality to improve patient outcomes demands a pioneering, rigorous and proven neuroscience-based approach, which could not be accomplished without the unwavering commitment of our team."

Key Points: 
  • "Introducing a new treatment modality to improve patient outcomes demands a pioneering, rigorous and proven neuroscience-based approach, which could not be accomplished without the unwavering commitment of our team."
  • GrayMatters Health's flagship product, Prism for PTSD, is the first PTSD treatment based on a digital brain-mechanism-specific biomarker associated with mental health disorders.
  • Prism for PTSD, now available in select US clinics, is the first prescribed self-neuromodulation device to receive FDA clearance to treat post-traumatic stress disorder (PTSD).
  • The treatment's efficacy and safety was recently demonstrated in a peer-reviewed article published in the Journal of Psychiatry Research .

eHub Contributor Report: What's Killing Your Fulfillment Business

Retrieved on: 
Thursday, March 14, 2024

SANDY, Utah, March 14, 2024 /PRNewswire/ -- As the ecommerce and fulfillment landscape continues to evolve, eHub has released a comprehensive report shedding light on the critical challenges faced by fulfillment businesses.

Key Points: 
  • SANDY, Utah, March 14, 2024 /PRNewswire/ -- As the ecommerce and fulfillment landscape continues to evolve, eHub has released a comprehensive report shedding light on the critical challenges faced by fulfillment businesses.
  • Titled "What's Killing Your Fulfillment Business," this report is a collaborative effort of industry leaders aiming to provide insights, solutions, and strategies for success in today's market.
  • In the report's introduction, eHub emphasizes the importance of learning from seasoned industry experts to navigate the complexities of the fulfillment landscape effectively.
  • Drawing on collective expertise, the report identifies common ailments plaguing fulfillment businesses and offers actionable cures to address them.